Beta Bionics, Inc. is facing a securities class action lawsuit after the FDA issued a Warning Letter concerning its insulin pump's quality and complaint handling. Despite initial positive analyst coverage downplaying the FDA's concerns as procedural, the full letter revealed serious safety risks, leading to a 72% stock price decline from $31.99 to under $9 between January and April 2026. The lawsuit alleges the company misled investors by minimizing over 18,000 unreported complaints and mischaracterizing FDA findings. Investors who bought shares between July 2025 and February 2026 may be eligible to recover losses, with a lead plaintiff deadline set for November 3, 2026.
S&P Global Ratings has upgraded EssilorLuxottica's long-term credit rating to A+ with a stable outlook, recognizing the company's strong organic growth, solid cash flow, and robust balance sheet. The rating agency highlighted EssilorLuxottica's strat...
Questrade now offers pre-market (7:30 am to 9:25 am ET) and post-market (4:00 pm to 4:15 pm ET) trading for equity options on 29 selected stocks and ETFs, including major names like AAPL and TSLA. This allows investors to respond to earnings reports ...
EssilorLuxottica announced that S&P Global Ratings has upgraded its long-term credit rating to A+ with a stable outlook. This upgrade recognizes the company's strong organic growth, consistent cash generation, and solid financial position. S&P also h...
EssilorLuxottica announced that S&P Global Ratings has upgraded its long-term credit rating to A+ with a stable outlook. This upgrade recognizes the company's strong organic growth, robust cash flow, and solid balance sheet. S&P also highlighted the ...
Man Group PLC has publicly disclosed an interest in 3.13% of RHI Magnesita N.V.'s ordinary shares, combining direct ownership and cash-settled derivatives as of October 22, 2026. Additionally, Man Group holds positions in Vesuvius plc, indicating str...
